Amarin Corp PLC News - AMRN

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Form 8-K - Current report

Amarin Receives National Reimbursement for VAZKEPA® in Italy

-- Italian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce...

Amarin Appoints Peter Fishman Chief Financial Officer

DUBLIN and BRIDGEWATER, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today...

Form 8-K - Current report

Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual

DUBLIN and BRIDGEWATER, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today...

Form 3 - Initial statement of beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update

-- Strong Cash Position of $306 Million; 9th Consecutive Quarter of Positive or Neutral Cash Balance Total Net...

Amarin Announces Two Upcoming Investor Events

-- Company to Report Third Quarter 2024 Financial Results Wednesday, October 30 –- -- Amarin to Hold Virtual...

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc...

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

DUBLIN, Ireland and BRIDGEWATER, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN...

Form 4 - Statement of changes in beneficial ownership of securities

Number sleven 6 hours ago

MrFred, Interesting observation. My first thought is obviously. If your company controls the BOD how are you not an insider.
Sleven,

👍️ 1

MrFred 7 hours ago

An insider of a company, as defined by the Securities and Exchange Commission (SEC), is an officer, director, or 10% shareholder of a company that has inside information into the company because of their relationship to the company or with an officer, director, or principal shareholder of the company. Me thinks that if the BOD are sitting as directors because you nominated them and a number of them are officers of your company, you are by definition an insider.

👍️ 1

JRoon71 7 hours ago

LB, my "agenda" is to maximize my return. I have a lot of shares riding on this. I don't short stocks (ever), and have no interest in this board, other than gathering as much info and data on AMRN as possible (especially since it is so thinly covered by analysts).

I spend way more time here than I would like, but I never imagined 4 years ago that we would be here today (the SP), so here I am.

Side note, I was one of the biggest LB fans back in the 80's. I grew up outside of Boston, and spent many a night watching the Big 4 spank the Lakers and Sixers. Not many teams compare to the 80's Celtics.

👍️0

JRoon71 7 hours ago

1. Denner is not an insider yet. He has not reached that threshold, and is not on the board. Thus he is not prohibited from shorting the stock.
2. Sarissa stated in their proxy filing with the SEC that they could employ shorting as a strategy with Amarin. It is stated in black and white.
3. I believe they (or their proxy, such as Morgan Stanley) have been shorting in order to use it as a springboard for the stock price when the time is right. Why else would there be 18M shares short almost this entire year? On 4/15/24 there were 18,190K shares short. On 12/13/24 there were 18,190K shares short. The short interest has oscillated around that number all year. Who would logically still have that exact many shares short when the stock is at 40 cents? I don't think there is malicious intent. In fact, the exact opposite - I think it is a strategic move by them.
4. Back to Morgan Stanley - follow their pattern of AMRN holdings over the past 12 quarters, in relationship to Sarissa's AMRN holdings. It's eye-opening.

Finally, does everyone think that driving the stock price down to 40 cents just occurred organically? I mean do people REALLY believe that?

I'm not saying I am 100% correct. I may certainly be wrong. But for the love of god, open your eyes. Sarissa got involved in this stock when it had climbed back to nearly $9 in early 2021. No, they hadn't made a purchase yet. But they were certainly analyzing it at that point.
Do you know that a current Amarin board member was HEAVILY trading AMRN options beginning in January of 2021, WELL before Sarissa ever made a single purchase?

You all can continue to see what you want to see, but there's a whole shit-ton of activity going on behind the scenes that we are not privy to.

👍️0

Nukemtiltheyglow 8 hours ago

Hi LBL; I muted numbnutz a long time ago.

👍️0

ziploc_1 9 hours ago

For significant increases in stock price, Amarin needs significant increases in earnings from the U.S...

Patented Lr Et EPA could be a way to produce those earnings.

With the previous success of the Reduce-It study, i.e.as to the safety and efficacy of the EPA drug, Vascepa, the FDA might now require only a short patient study of this new EPA drug of Amarin's...Lr Et EPA

👍️0

Chromosome 9 hours ago

Speaking of France does anyone have any information on timing in 2025 other than “sometime in 2025” for reimbursement. I have not been able to find anything in their filings. TIA.

👍️0

Mr Stockboy 10 hours ago

Sarissa isn't shorting unless Denner enjoys fines and jail time. Denner's an insider with his own BOD so his hands are tied like a CEO. And it's why I like Sarissa here. Denner bought to win, and he will win in 2025, and so will the rest of us who buy and hold. Big wins! Really big wins! I'd much prefer one of you write about all the countries we're now approved in... Other than France (maybe Germany) AMRN is up for sale.

👍️ 3

lizzy241 10 hours ago

North, It's strange that management has not announced their presence at the JPM health care conf. Maybe they are saving their shackles for other necessary expenses.

👍️0

lizzy241 10 hours ago

LBL, It's Good to hear from you. I totally agree with you. Please see the link below re the new rules for HF short sales. There's no way Sarissa would mess around with the stock price. They have too much on their plate, and that's not even doable with the $.50 cent stock. It would be a violation and lack of prudence on the part of the entire management team from Denner down to the last elected BOD. You know what they say about assumptions. Take care.

https://foleyhoag.com/news-and-insights/publications/alerts-and-updates/2024/october/sec-short-sale-disclosure-rules-upcoming-compliance-date/

👍 1

Whalatane 11 hours ago

Retiredceo. re the stress test in women. Wife asked about your wife's results . Was relieved but not surprised ...cited
Previous research has suggested that up to 30% of women undergoing ECG stress testing may have false positive ECG tests (F+), many times higher than in men.
Various reasons this occurs .
Kiwi

👍️0

rosemountbomber 11 hours ago

So for someone to "sell short" would they have to "sell shares"?

In this letter Sarissa says this:

We remain long-term shareholders and have been purchasing shares at these depressed prices, as will be detailed in tomorrow’s 13D filing. We have never sold any shares of Amarin and have only increased our position since we made the investment.

https://www.businesswire.com/news/home/20231204232430/en/Sarissa-Capital-Believes-Amarin-Stock-Is-Meaningfully-Undervalued-and-Has-Increased-Its-Ownership

👍 2

hayward 13 hours ago

nolean 09

In all his accounts I believe he has 3 or 4 I could be wrong but I remember his cost was lower than 3.45 IMO I should say it was posted that his average PPS was lower and in his filing not sure what form is were he stated he using the short/long strategy I will try to find it

Michael

👍️0

CaptBeer 14 hours ago

More on the TRANSFORM Trial (using AI and CCTA)

👍️ 1

Whalatane 15 hours ago

Wow , fantastic . Thx for the response
Kiwi

👍️0

noelan_s09 15 hours ago

Denner's cost average is ~$3.45.

Noel

👍️0

hayward 15 hours ago

Larrybirdlegend

Unfortunately its true he is using it as a hedge it was posted here in a filing a while back that he uses a short/long strategy. That is how he brought his average cost down from $4 to around $2

Michael

👍️0

CaptBeer 15 hours ago

I asked Dr. Bhatt if IPE was going to be used in the upcoming TRANSFORM Trial:

https://cardiovascularbusiness.com/topics/artificial-intelligence/new-cardiac-prevention-paradigm-explored-transform-trial-using-ai-and-ccta

His answer: “Yes, icosapent ethyl (IPE) will be part of the intense medical management strategy.”

It’s the EPA Stupid!

👍️ 3

ramfan60 15 hours ago

Great news Retired...... nice lifestyle as well...all the best!

👍️0

CaptBeer 16 hours ago

RIR (Residual Inflammatory Risk):
The anti-inflammatory benefits of high-dose EPA mentioned here:
https://www.ahajournals:.org/doi/full/10.1161/ATVBAHA.124.319983#sec-3
It’s the EPA Stupid!

👍️ 1

Retiredceo 17 hours ago

False positive on the stress test. There are zero issues.

We shoot, grow and fish for most of our food. That was part of the discussion with the doc. Doc said she could start eating French fries and ice cream every day and wouldn’t live long enough to block up her heart. She’s 60 years old.

“Body of a 20 year old”.

Whew

Thank you for the responses and concern.

👍️ 4

Larrybirdlegend 17 hours ago

This is the most ridiculous thing I've ever seen posted here

There is no way sarissa is shorting this stock

They have a fiduciary duty and to even suggest that makes me believe you have some other agenda here

Denner has more motivation than anyone else to drive value and I am certain he will

👍️ 6

Number sleven 18 hours ago

https://www.isrctn.com/ISRCTN15140257
Sleven,

👍️ 1

Number sleven 20 hours ago

JRoon,
https://www.merriam-webster.com/dictionary/evidence
I asked for evidence, not proof. You don't seem to understand the difference. Good evidence doesn't always lead to the correct conclusion, but that evidence should be the first step towards reaching a conclusion. The search for evidence is research. That takes effort.
Are you familiar with Roseanne Roseannadanna?
Sleven,

👍️ 1

DMC8 23 hours ago

I don’t know if the Supreme Court will even entertain the extension of Certiorari or grant the Certiorari in the first place.

Typo error in the article, should be Amarin versus HIKMA.
https://patentlyo.com/patent/2025/01/supreme-preview-skinny.html

👍 1

ORBAPU 1 day ago

There is no proof. Only speculation.

👍️0

JRoon71 1 day ago

Sleven, would you mind posting proof that Sarissa is not shorting?

Considering their statement that this is one strategy that they could employ (in their proxy statement, filed with the SEC), it is not a stretch.

Simply because you can't prove something, does not make it false.

You believe Amarin is going to prevail in their lawsuit, but have no proof of that, other than your own belief.

You thought BRAVE was going to show a positive outcome, without any proof of that, other than your own belief.

I believe Sarissa (or their proxies) are responsible for some or all of the short interest in AMRN. They have stated they may do that. I believe them.

👍 1

rosemountbomber 1 day ago

I am basically saying the opposite. I don't have any evidence to believe Denner is shorting the stock.

👍️0

Denisk 1 day ago

RMB, SLEVEN. IMO this statement that Denner has been shorting the stock does not make sensedue to the following facts:
The total number of shares traded since Jan 8, 2024 to DEC 31, 2024 was 390.960 million shares, that’s an average of 1.570 million shares traded daily. (785 thousand shares bought and sold daily).
The high of the year was $1.37 per share and the low was $0.43 with a total monthly shorted shares of 4.87% throughout the year (per Nasdaq short interest list throughout the year). So let us say Denner shorted 100 thousand shares daily(which is roughly 12 % of the average traded shares daily, not counting other institutions or retail holders shorting) and he realized a net gain of $0.94 that would give him a profit of approximately $23 million and bring his average to $3.06 from his original purchase price of $4.60.
I just don’t think that is possible and wouldn’t that expose him to numerous lawsuits?
Can you explain to me how you can state that is was shorting the stock during this all time?

👍️0

north40000 1 day ago

Or earlier at JPM HealthCare Conference, 01/13-15/2025. Oral presentation? Poster?

👍️0

Whalatane 1 day ago

Retiredceo re . Angiogram now set for Jan 3 and meeting with their top doc.
Hope things went well today .
Kiwi

👍️0

Number sleven 1 day ago

RMB, A number of people on this board create natives. Then they site those natives as proof. Be careful what you take from this board. You understand. These people said what I said after I said it, so obviously it's true.
Sleven,

👍️ 3

rosemountbomber 1 day ago

A few people have mentioned Denner/Sarissa having a short position here, but I haven't seen anything corroborating or confirming that

👍️0

Number sleven 1 day ago

https://www.courtlistener.com/docket/59859757/dr-reddys-laboratories-inc-v-amarin-pharma-inc/?page=2
Sleven,

👍️0

Number sleven 1 day ago

JRoon Would you mind posting your evidence of a Sarissa short position?
Sleven,

👍 1

Number sleven 1 day ago

Ex,
https://codes.findlaw.com/us/title-35-patents/35-usc-sect-284/#:~:text=Damages&text=Upon%20finding%20for%20the%20claimant,as%20fixed%20by%20the%20court.
Sleven,

👍️ 1

Denisk 1 day ago

FROM THAT ARTICLE , here is a comment from the readers: Stephen Newman
• 3rd+
Director of Preventive Cardiology at HCNT and CEO Iatros Synergy Corp
1mo

John, thank you for sharing this study. From a preventive cardiology perspective, the findings reinforce EPA’s role in modulating inflammation and oxidative stress, key drivers of atherosclerosis. The downregulation of immune-related genes and upregulation of Nrf2-regulated antioxidant pathways like NQO1 align with the cardiovascular benefits seen in studies like REDUCE-IT highlighting EPA’s potential beyond lipid lowering, emphasizing its impact on plaque stabilization and immune modulation, which are critical in preventing cardiovascular events! Stephen

John Nelson MD,FACC,FNLA,FASNC
Author
Director at California Cardiovascular Institute
1mo

All excellent points.Prescription EPA is one of the most under-utilized CVOT proven,guideline recommended drugs.This is the first lipid lowering drug that the proven CVOT CV risk reduction was NOT primarily related to lipid effects(ie LDL-C/HDL-C/apo B/non HDL-c/RLP-c) but to the serum level of EPA and its myriad of pleiotropic effects which we are only just starting to understand.Its array of anti-inflammatory,anti-thrombotic,anti-oxidant and pro-resolving effects are amazing.

2 Re

👍️ 11

JRoon71 1 day ago

Last year, Amarin made a preliminary announcement of Q4 results on January 10th. It was a good quarter, and the SP jumped 32% in one day.

It will be interesting to see if this will be again be the "launching pad" for a price recovery. Announce good Q4 results. Announce commencement of share BB. Sarissa buys more (and they close their short position at the same time). Some sort of announcement related to an AG or something operational.

The next few months are going to be wild.

👍 1

DMC8 2 days ago

https://www.linkedin.com/pulse/eicosapentaenoic-acid-induces-anti-inflammatory-cells-john-szgic?utm_source=share&utm_medium=member_ios&utm_campaign=share_via

👍️ 6

JRoon71 2 days ago

It's also based on lost profits, not lost revenue.

They would have to apply cost of goods sold and a factor for salesforce and marketing costs.

👍️0

Number sleven 2 days ago

Ex, Take a look at how damages were assessed in GSK v Teva.
Sleven,

👍 1

exwannabe 2 days ago

Hayward, The assessment of damages is not based on sales by Hikma. It's based on the revenue lost by Amarin.
True, but would be an interesting question of how that is determined. Just taking the pre generic to post generic revenue reduction is not valid as certainly the generic competition even in the non-infringing indication is real.

I imagine Amarin would argue the loss should be their hit prorated to relative size of the indications. This would be very substantial.

I imagine Hickma would argue it should Hickma's sales quantity of the infinging sales valued per AMRN's sales metrics. That would be fairly modest (though nothing to sneeze at).

Does the treble damage rule apply in a case such as this where the argument is not over the technical details of the infringement? I have no clue on that one.

👍️0

rosemountbomber 2 days ago

Our best and quickest route was the Marjac/North legal action but for some reason Amarin decided not to join thus giving the other side the standing get out of jail card. These current cases, for tge time being are noise.

👍️ 1

ramfan60 2 days ago

Regardless....... Hikma will have this potential HUGE liability as discovery starts to uncover the details of the infringement. This will not go unnoticed by a potential BP buyer of AMRN. The longer it goes and if in our favor, the liability increases..... who blinks first. Of course we won't be counting on this lawsuit as current investors to drive the share price but it is something an acquirer will be interested in.

👍️0

Chromosome 2 days ago

I am with you on that one JR… the lawsuits for me are not a part of the base case. I personally think getting a new formulation in market that is patent protected has a higher likelihood of happening sooner that a final resolution of these lawsuits. Having said that I feel there is a greater than 0% chance of a settlement before that for some of the reasons you stated. JMO

Damages they would maybe pay in what like 10 years?They will just appeal the decision for years on end.

👍️0

JRoon71 2 days ago

Sure, but what does that tell you about their confidence in this lawsuit?

This is not Hikma's first rodeo. They get sued all the time. It is literally part of their business model. They have over 800 products they sell, do nearly $3B in revenue, have a market cap of $5.5B, and I doubt they are that worried about Amarin. If they were, they would have withdrawn from selling IPE.

And even if Amarin is somehow still around in 4 or 5 years, and happens to win the appeal of the appeal, they then have a protracted fight about the damages. And there will be extensive analysis of how to arrive at "lost profits" for Amarin. And this process will drag on for years.

Look at GSK vs. Teva. Very similar case. Filed in 2014, still ongoing to this day. They're actually talking about a potential new trial. https://casetext.com/case/glaxosmithkline-llc-v-teva-pharm-us-3 . Amarin's case was only filed in 2020. How much money do you think GSK has spent on this trial? And Teva? And do you think Hikma can outlast Amarin?

The company is going to be sold long before this lawsuit ever has any impact on Amarin. A final, post-appeal decision is at least 4 years away. The only thing happening right now is lawyers getting rich.

I know others see it differently, and that is fine. I'm more concerned with Amarin's actual operations, not in a lawsuit that will likely never amount to anything meaningful for Amarin.

👍️ 2

the_kube 2 days ago

If Hikma continues with the stall tactics, aren’t they just adding to potential damages they would have to pay?

👍️0

Number sleven 2 days ago

Hayward, The assessment of damages is not based on sales by Hikma. It's based on the revenue lost by Amarin.
Sleven,

👍️0

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Amarin Corp PLC (AMRN)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

AMRN News

Form 8-K - Current report

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Amarin Appoints Peter Fishman Chief Financial Officer

Form 8-K - Current report

Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual

Form 3 - Initial statement of beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update

Amarin Announces Two Upcoming Investor Events

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

AMRN Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Amarin Corp PLC (AMRN) News

Amarin Corp PLC (AMRN)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

AMRN News

Form 8-K - Current report

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Amarin Appoints Peter Fishman Chief Financial Officer

Form 8-K - Current report

Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual

Form 3 - Initial statement of beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update

Amarin Announces Two Upcoming Investor Events

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

AMRN Discussion

Your Recent History

Go Ad-Free